Genomic analysis of circulating tumor DNA (ctDNA) from patients with HR+, HER2-mutant metastatic breast cancer (MBC) enrolled in SUMMIT: mechanisms of acquired resistance to neratinib plus fulvestrant plus trastuzumab (N plus F plus T)

被引：0
|
作者：
Ma, Cynthia
Waisman, James
Brufsky, Adam M.
Yang, Eddy S.
Wildiers, Hans
Crown, John P.
Piha-Paul, Sarina A.
Suga, Jennifer M.
Garcia-Saenz, Jose Angel
Gambardella, Valentina
Guerrero, Angel
Stemmer, Salomon
Bose, Ron
Novara-Demgen, Tonya
DiPrimeo, Daniel
Eli, Lisa D.
Jhaveri, Komal
机构：
来源：
CANCER RESEARCH | 2023年 / 83卷 / 05期
关键词：
D O I：
10.1158/1538-7445.SABCS22-PD17-01
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
PD17-01
引用
收藏
页数：3
相关论文
共 50 条
  • [21] TRASTYVERE study: A retrospective analysis of HER2-positive metastatic breast cancer (MBC) patients treated in Spain with lapatinib (L) plus trastuzumab (T)
    Gavila, Joaquin
    Bermejo, Begona
    Rodriguez-Lescure, Alvaro
    Lao Romera, Juan
    Manso, Luis
    Brunet, Joan
    Munoz, Eva
    Santisteban, Marta
    Rodriguez, Cesar A.
    Santaballa, Ana
    de la Haba, Juan
    Sanchez-Rovira, Pedro
    Ruiz-Borrego, Manuel
    Angel Garcia-Saenz, Jose
    Cortes, Javier
    Llombart, Antonio
    CANCER RESEARCH, 2015, 75
  • [22] Neratinib plus capecitabine (N plus C) vs lapatinib plus capecitabine (L plus C) in Asians with HER2+metastatic breast cancer (MBC) previously treated with two or more HER2-directed regimens: A Pan-Asian analysis of the phase III NALA trial
    Dai, M. S.
    Feng, Y. H.
    Chen, S. W.
    Masuda, N.
    Sangai, T.
    Yau, T.
    Kwong, A.
    Ngan, R.
    Yap, Y. S.
    Ang, P. C. S.
    Ow, S.
    Lee, K. S.
    Kim, S. B.
    Chung, H. C.
    Keyvanjah, K.
    Bebchuk, J.
    Chen, M-C. J.
    ANNALS OF ONCOLOGY, 2020, 31 : S1259 - S1259
  • [23] A phase II trial of neratinib (NER) or NER plus fulvestrant (FUL) (N+F) in HER2 mutant, non-amplified (HER2mut) metastatic breast cancer (MBC): Part II of MutHER.
    Ma, Cynthia X.
    Luo, Jingqin
    Freedman, Rachel A.
    Pluard, Timothy
    Nangia, Julie
    Lu, Janice
    Valdez-Albini, Frances
    Cobleigh, Melody
    Jones, Jason
    Lin, Nancy U.
    Winer, Eric
    Marcom, P. Kelly
    Thomas, Shana
    Anderson, Jill
    Haas, Brittney
    Hamann, Kimberly M.
    Bryce, Richard
    Lalani, Alshad S.
    Carey, Lisa
    Goetz, Matthew
    Gao, Feng
    Kimmick, Gretchen
    Pegram, Mark
    Ellis, Matthew J.
    Bose, Ron
    CANCER RESEARCH, 2021, 81 (13)
  • [24] Baseline circulating tumor DNA (ctDNA) analysis in Asian women with HR+/HER2-advanced breast cancer (ABC) receiving ribociclib plus endocrine therapy in the Phase Ib MONALEESASIA trial
    Yap, Yoon-Sim
    Su, Faye
    Solovieff, Nadia
    Ito, Yoshinori
    Masuda, Norikaza
    Ishikawa, Takashi
    Aruga, Tomoyuki
    Kim, Seung Jin
    He, Wei
    Gazdoiu, Mihaela
    Chiu, Joanne
    CANCER RESEARCH, 2019, 79 (13)
  • [25] EXPANDED EXPERIENCE WITH INTRAVENOUS OR ORAL VINORELBINE (VNR) PLUS TRASTUZUMAB (T) IN CHEMONAIVE PATIENTS WITH HER-2 OVEREXPRESSING METASTATIC BREAST CANCER (MBC)
    Bernardo, A.
    Palumbo, R.
    Villani, G.
    Strada, M. R.
    Bernardo, G.
    ANNALS OF ONCOLOGY, 2004, 15 : 27 - 27
  • [26] Results from CONTESSA 2: A multinational, multicenter, phase 2 study of tesetaxel (T) plus a reduced dose of capecitabine (C) in patients (pts) with hormone receptor plus (HR+), HER2-metastatic breast cancer (MBC) not previously treated with a taxane.
    Schwartzberg, Lee S.
    Bondarenko, Igor
    Tolaney, Sara M.
    Seidman, Andrew David
    O'Shaughnessy, Joyce
    Shparyk, Yaroslav V.
    Chung, Chi-Feng
    Lu, Yen-Shen
    Chic, Nuria
    Panasci, Lawrence C.
    Chae, Yee Soo
    Recalde, Sabela
    Hotko, Yevhen
    Gomez, Patricia
    Shaw Wright, Gail Lynn
    Anthony Dacosta, Noshir
    Vatandoust, Sina
    O'Connell, Joseph P.
    Wei, Thomas
    Rugo, Hope S.
    JOURNAL OF CLINICAL ONCOLOGY, 2021, 39 (15)
  • [27] Analysis of the pan-Asian subgroup of patients in the NALA Trial: a randomized phase III NALA Trial comparing neratinib plus capecitabine (N plus C) vs lapatinib plus capecitabine (L plus C) in patients with HER2+metastatic breast cancer (mBC) previously treated with two or more HER2-directed regimens
    Dai, Ming Shen
    Feng, Yin Hsun
    Chen, Shang Wen
    Masuda, Norikazu
    Yau, Thomas
    Chen, Shou Tung
    Lu, Yen Shen
    Yap, Yoon Sim
    Ang, Peter C. S.
    Chu, Sung Chao
    Kwong, Ava
    Lee, Keun Seok
    Ow, Samuel
    Kim, Sung Bae
    Lin, Johnson
    Chung, Hyun Cheol
    Ngan, Roger
    Kok, Victor C.
    Rau, Kun Ming
    Sangai, Takafumi
    Ng, Ting Ying
    Tseng, Ling Ming
    Bryce, Richard
    Bebchuk, Judith
    Chen, Mei Chieh
    Hou, Ming Feng
    BREAST CANCER RESEARCH AND TREATMENT, 2021, 189 (03) : 665 - 676
  • [28] Dalpiciclib plus fulvestrant in HR+/HER2-advanced breast cancer (ABC): Updated analysis from the phase III DAWNA-1 trial
    Zhang, P.
    Zhang, Q. Y.
    Hu, X.
    Li, W.
    Tong, Z.
    Sun, T.
    Teng, Y.
    Wu, X.
    Ouyang, Q.
    Yan, X.
    Cheng, J.
    Liu, Q.
    Feng, J.
    Wang, X.
    Xu, G.
    Wu, F.
    Xia, B.
    Xu, B.
    ANNALS OF ONCOLOGY, 2022, 33 (07) : S642 - S643
  • [29] Efficacy and CNS progression analysis from the randomized phase 2 trial of neratinib plus paclitaxel vs trastuzumab plus paclitaxel as first-line treatment for HER2+metastatic breast cancer (NEfERTT)
    Awada, Ahmad
    Colomer, Ramon
    Bondarenko, Igor
    Inoue, Kenichi
    Badwe, Rajendra A.
    Demetriou, Georgia
    Wang, Xiaojia
    Smirnov, Vitaly
    Lee, Soo-Chin
    Mehta, Ajay O.
    Kim, Sung-Bae
    Shen, Zhen-Zhou
    Bachelot, Thomas Denis
    Goswami, Chanchal
    Deo, S. V. S.
    Bose, Ron
    Wong, Alvin
    Xu, Feng
    Bryce, Richard
    Carey, Lisa A.
    JOURNAL OF CLINICAL ONCOLOGY, 2015, 33 (15)
  • [30] Preliminary results from TRASTYVERE study: A retrospective analysis of HER2-positive (HER2) metastatic breast cancer (MBC) patients treated in Spain with lapatinib (L) plus trastuzumab (T).
    Gavila, Joaquin
    Bermejo, Begona
    Manso, Luis
    Munoz, Eva
    Anton, Antonio
    Brunet, Joan
    Rodriguez-Lescure, Alvaro
    Augusto Rodriguez, Cesar
    Santaballa, Ana
    Sanchez-Rovira, Pedro
    de la Haba-Rodriguez, Juan
    Santisteban, Marta
    Ruiz Borrego, Manuel
    Cortes, Javier
    Llombart-Cussac, Antonio
    JOURNAL OF CLINICAL ONCOLOGY, 2014, 32 (15)
12345